BTAI

BioXcel Therapeutics Incdistress 10/10 · high distress / dilution risk

$0.88+0%today-87% from 52w high

bioxceltherapeutics.com29 employeesFounded 2017New Haven, CTDrug Manufacturers - Specialty & Generic

Psychiatry / CNS 2

Lead: acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting · est. market ~$8B (approx, global)

Revenue

pre-revenue

Liquidity

$17M

Runway

0.3 yrs

Shares 1y

+112%

Price & events

-51.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.0%

+1.2%

-30.2%

-20.0%

-51.6%

-51.4%

-95.4%

-99.8%

-99.9%

All

Overview

Market Cap: $27.18M
Enterprise Value: $87.85M
Volume: 53.95K
52 Week Range: $0.80 – $6.80
Total Shares: 30.88M
Float Shares: 26.36M
Short %: 12.08%
% Held by Insiders: 3.65%
% Held by Institutions: 18.72%
RVOL: 0.04x
Beta: 0.27

Pipeline stages · 1 programs

BXCL501 Sublingual Film

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 2 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2025-10-07	Phase 2	BXCL501 Sublingual Filmfast track	Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation	33	completed
2025-08-15	Phase 3	BXCL501fast track	Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders	452	completed

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 9

November 14, 2026Confirmed 100%PDUFAPDUFAIGALMI · PDUFA target action dateSEC 8-K
April 1, 2026filing acceptanceFiled (NDA/BLA)IGALMI · FDA accepted supplemental New Drug ApplicationSEC 8-K
first quarter of 2026regulatory submissionFiled (NDA/BLA)BXCL501 · Submit sNDA for BXCL501 for acute agitation including patient-dyad study and SERENITY At-Home Phase 3 trialSEC 8-K
early first quarter of 2026regulatory submissionFiled (NDA/BLA)IGALMI · sNDA submission for label expansion to at-home useSEC 8-K
second half of 2025readoutPhase 3BXCL501 · Topline results from SERENITY At-Home pivotal Phase 3 trial evaluating safety of BXCL501 in at-home setting.SEC 8-K
2025-08-14fda agreementBXCL501 · Positive pre-sNDA meeting comments received from FDA; alignment on sNDA content and format for at-home useSEC 8-K
2025-08-14fda agreementPositive preliminary meeting comments from FDA regarding pre-sNDA meeting for planned sNDA submissionSEC 8-K
2024-11-21fda agreementFifth Amendment to Credit Agreement: Lenders waived going concern qualification, minimum revenue covenant, and $50M capital raise requirement; added new capital raise covenants and increased interest rate to 13%.SEC 8-K
September 5, 2024trial initiationsecondaryPhase 3BXCL501 · Initiated patient enrollment in Phase 3 SERENITY At-Home trial.SEC 8-K

Approved drugs (1)

IGALMIDEXMEDETOMIDINE HYDROCHLORIDE2022 · Prescription

Capital structure — dilution & financing

Shares out: 30,877,605 · 3 offerings/1y · 1 PIPEs

2026-07-068-Kmaterial_agreement
2026-04-178-Kprivate_placement
2026-03-118-Kmaterial_agreement
2026-03-11424B5offering
2025-08-18424B5offering
2025-08-06424B5offering
2025-04-038-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-04-02HC Wainwright & Co.Buy
2026-03-17Rodman & RenshawBuy
2026-03-05HC Wainwright & Co.Buy
2025-09-15HC Wainwright & Co.Buy
2025-09-12MizuhoNeutral
2025-08-28HC Wainwright & Co.Buy

Competitors — acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.